Tuesday, November 22, 2016 8:57:54 PM
I see that the NASH space is huge and Allergan paying $1.7 billion for TBRA really caught my attention. Especially since TBRA failed on the primary endpoint of study, but did well in the fibrosis score -- although FDA says that is now an approvable endpoint. Which is why Allergan bought Tobira. But if Conatus works in Liver Cirhossis that could be a bigger market as there are no treatments for that. NASH fibrosis will have some competitors like Intercept Pharmaceuticals, and Tobira.
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM